# Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery

> **NCT00880542** · PHASE2 · TERMINATED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 7 (actual)

## Conditions studied

- Sarcoma

## Interventions

- **DRUG:** sorafenib
- **DRUG:** Ifosfamide

## Key facts

- **NCT ID:** NCT00880542
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-08
- **Primary completion:** 2010-11
- **Final completion:** —
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** The study lost funding.
- **Last updated:** 2020-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00880542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00880542, "Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00880542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*